Concentrations of Serum Brain Injury Biomarkers Following SARS-CoV-2 Infection in Individuals with and without Long-COVID-Results from the Prospective Population-Based COVI-GAPP Study.

Publication date: Jun 26, 2023

It is unknown whether neurological symptoms are associated with brain injury after SARS-CoV-2 infections and whether brain injury and related symptoms also emerge in Long-COVID patients. Biomarkers such as serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) can be used to elucidate neuro-axonal and astroglial injuries. We investigated whether these biomarkers are associated with COVID-19 infection status, associated symptoms and Long-COVID. From 146 individuals of the general population with a post-acute, mild-to-moderate SARS-CoV-2 infection, sNfL and sGFAP were measured before, during and after (five and ten months) the infection. Individual symptoms and Long-COVID status were assessed using questionnaires. Neurological associated symptoms were described for individuals after a mild and moderate COVID-19 infection; however, sNfL (p = 0. 74) and sGFAP (p = 0. 24) did not change and were not associated with headache (p = 0. 51), fatigue (p = 0. 93), anosmia (p = 0. 77) or ageusia (p = 0. 47). In Long-COVID patients, sGFAP (p = 0. 038), but not sNfL (p = 0. 58), significantly increased but was not associated with neurological associated symptoms. Long-COVID status, but not post-acute SARS-CoV-2 infections, may be associated with astroglial injury/activation, even if neurological associated symptoms were not correlated.

Open Access PDF

Concepts Keywords
Astroglial COVID-19
Biomarkers GFAP
Covid neurofilament light chain
Headache NfL
Months SARS-CoV-2
serum biomarker


Type Source Name
disease MESH SARS-CoV-2 Infection
pathway REACTOME SARS-CoV-2 Infection
disease VO population
disease MESH infection
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Long COVID
disease VO Canada
disease MESH complications
drug DRUGBANK Coenzyme M
disease IDO symptom
disease IDO history
disease VO organization
disease MESH syndrome
disease IDO blood
disease VO time
drug DRUGBANK L-Phenylalanine
disease VO unvaccinated
disease MESH seroconversion
disease VO volume
disease VO protocol
disease VO storage
disease IDO assay
disease IDO acute infection
disease VO USA
disease IDO facility
disease MESH sore throat
disease VO ANOVA
disease VO vaccinated
disease MESH Reinfection
disease VO age
disease MESH Arthralgia
disease MESH Rhinitis
disease VO frequency
disease IDO process
drug DRUGBANK Oxygen
drug DRUGBANK Etoperidone
drug DRUGBANK Succimer
disease MESH coronavirus infections
disease MESH neurological disorders
disease MESH Neuroinflammation
disease MESH Acute Ischemic Stroke
disease MESH mild cognitive impairment
disease MESH dementia
disease MESH Critically Ill
disease MESH death

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *